The Food and Drug Administration says its ongoing safety review of the nation’s main abortion pill will continue into next ...

A court-ordered status update said the agency does not plan to implement any restrictions while its review of the pill ...

The FDA, in a Wednesday legal filing, said that its much-anticipated review of the abortion drug mifepristone won’t be ...

The FDA says its ongoing safety review​ of the nation's main abortion pill​ will continue into next year, a timeline quickly condemned by abortion rights foes hoping to see the drug's use curtailed.

The FDA says its safety review of mifepristone will continue into 2027, with findings expected by March before the agency ...

Three Republican-led US states are testing a novel legal argument as they seek to stem the flow of abortion pills to residents who can still obtain them from out-of-state providers despite their ...

The administration is delaying this report because attacks on medication abortion will backfire with voters, but extremists will try to ban abortion as soon as the election is over.” ...

The U.S. Food and Drug Administration said late Wednesday that it expects to complete its long-awaited safety review of abortion pills by mid-December and issue a report evaluating the results by ...

The effort comes as federal officials continue reviewing regulations governing medication abortions. Current FDA guidelines allow abortion pills to be prescribed through telehealth without requiring ...

The Food and Drug Administration (FDA) has postponed until perhaps March 2027 the release of a safety study on the abortion pill mifepristone, delaying any attempts to end telehealth prescriptions for ...

The FDA says its safety review of mifepristone will continue into 2027, with findings expected by March before the agency ...